BLACK WEEKSViales −15% · kits −10% · resto −5%con el códigoEnvío gratis en Alemania a partir de 200 €

Esta página se ha traducido automáticamente y puede contener errores. ¿Eres hablante nativo? Nos encantaría recibir tus comentarios y correcciones.Enviar comentarios

The Peptide Desk The Peptide Desk

Esta información tiene únicamente fines de investigación y educativos. No son recomendaciones médicas. Los productos no están aprobados para uso humano. Para cuestiones de salud, consulta a un médico.

Enciclopedia

Avanafil (Stendra, Spedra)

The fastest PDE-5 inhibitor: peak levels in 30 to 45 minutes, a measurable effect from 10 to 15 minutes and high selectivity over PDE1, PDE6 and PDE11.

10 min read 10 sources

Branched molecule model of dark blue, light blue, white and one green sphere floats above a white podium with a glowing rim in a bright lab, symbolic image for avanafil
Compound approved · in the US since 2012

Summary

At a glance

Sources checked on 26 Oct 2026

Earliest difference from placebo
10 minutes

stopwatch trial with 440 men, at the highest study dose2

More selective for PDE5 than PDE6
121 -fold

sildenafil and vardenafil 16- to 21-fold in the same lab5

Half-life
~5 hours

per the US label, peak level fasted after 30 to 45 minutes7

Phase 3 on the registry
7 trials

all completed, plus 11 phase 1 and 4 phase 4 trials9

  • Avanafil inhibits the enzyme PDE5. The messenger cGMP persists longer, with sexual arousal an erection forms more easily. Without arousal nothing happens.107
  • In the lab avanafil was 121-fold selective over PDE6, more than 10,000-fold over PDE1 and more than 19,000-fold over PDE11, clearly more than older members of the class.5
  • In the registration trial with 646 men intercourse succeeded in 41 to 57 percent of attempts at the end, with placebo in 27 percent. In the stopwatch trial the difference showed from 10 to 12 minutes.72
  • The most common side effect is headache, which rises with the dose. Combined with nitrates it is life-threatening, strong CYP3A4 inhibitors raise the level up to 13-fold.7
  • Avanafil has been approved in the US since 2012. Everything here is the state of research, not a recommendation.8
Ficha

Updated October 2026

Class
Second-generation PDE-5 inhibitor

Stendra, Spedra

Use
Oral

on demand, about 15 to 30 minutes before, at most once in 24 hours

Onset
Peak levels after 30 to 45 minutes

significant effect from 10 to 15 minutes

Half-life
About 5 hours

US label, 6 to 17 hours (EU SmPC)

Window
Beyond 6 hours
Status
Clinically approved

FDA 2012, EU 2013

Sizes
100 to 200 mg

2 sizes in the shop

Contenido 15 sections
  1. De un vistazo
  2. What is avanafil?
  3. How it works
  4. Pharmacokinetics: fast in, fast out
  5. Use and dosing
  6. Avanafil vs sildenafil vs tadalafil
  7. What the research shows
  8. Estado de la investigación
  9. Side effects
  10. Safety and interactions
  11. Storage
  12. Compuestos relacionados
  13. Preguntas frecuentes
  14. Glosario
  15. Fuentes

What is avanafil?

Avanafil is the youngest of the four approved PDE-5 inhibitors and was designed as a refinement of the class: the same target as sildenafil, tadalafil and vardenafil, but a faster onset and an overall sharper selectivity for that target. The molecule, a pyrimidine-5-carboxamide, was discovered at Mitsubishi Tanabe in Japan. It has been approved in the US as Stendra since 2012 and in the EU as Spedra since 2013.

It is taken as a tablet on demand, about 15 to 30 minutes before planned activity according to the EU prescribing information. The US label allows as little as 15 minutes, which makes avanafil the member of the class with the shortest lead time. Its window extends beyond six hours in the trials, well short of the roughly 36 hours of tadalafil. You can get avanafil as tablets of 100mg or 200mg, 4 tablets per blister.

This information is for research and educational purposes only. No medical advice.

How it works

During sexual arousal, nerve endings in the erectile tissue release nitric oxide. That raises the messenger cGMP inside the smooth muscle cells, the muscle relaxes, the feeding arteries widen and the tissue fills with blood. The enzyme phosphodiesterase type 5 (PDE5) breaks cGMP down again and so ends the signal. Avanafil blocks PDE5 and the messenger persists longer. An erection forms more easily and holds more reliably. Without arousal the chain never starts, which is why nothing happens without stimulation.

What sets avanafil apart from the older agents is selectivity. Kotera and colleagues (Journal of Urology 2012) tested it against eleven phosphodiesterase isozymes: PDE5 is inhibited with an IC50 of 5.2 nM, selectivity over PDE6 is 121-fold (sildenafil and vardenafil 16- to 21-fold), over PDE1 more than 10,000-fold (sildenafil 375-fold) and over PDE11 more than 19,000-fold (tadalafil 25-fold). PDE6 sits in the retina and is behind the blue tinge seen with sildenafil, PDE1 in heart and vessels, PDE11 among other places in skeletal muscle, where the back pain under tadalafil is thought to originate. Less binding to those off-targets should in theory mean fewer side effects beyond the intended one. The trial data fit that expectation.

Where it acts

Where avanafil acted in studies

Tap a point or a card. Colour = PDE5, grey = observed in studies.

  1. Erectile tissue

    Inhibits PDE5, cGMP persists, erection with arousal easier10

    PDE5
  2. Retina

    121-fold less inhibition of PDE6, one case of changed colour vision5

    Observed in trials
  3. Blood pressure

    With nitroglycerin blood pressure fell more than without7

    Observed in trials
  4. Liver

    Breakdown via CYP3A4, strong inhibitors raise the level up to 13-fold7

    Observed in trials
  5. Back

    Back pain 1.1 to 3.2 percent, without a clear dose relationship7

    Observed in trials

Targets in the ChEMBL database10

Compound CHEMBL1963681: one recorded mechanism, Inhibitor, direct binding.

Phosphodiesterase 5A
Gene
PDE5A
UniProt
O76074
ChEMBL
CHEMBL1827
Action
Inhibitor, direct binding
Close-up of a translucent, widened blood vessel in which blue and white molecule chains dock onto grey enzyme blocks on the inner wall
Avanafil blocks PDE5, the vessels stay wide for longer. Symbolic image.

Pharmacokinetics: fast in, fast out

Taken fasted, avanafil reaches its peak level after a median of 30 to 45 minutes, per the prescribing information. A high-fat meal pushes the peak back by about 1.1 to 1.25 hours and lowers it by roughly 39 percent while total absorption barely changes (minus 3.8 percent). That is why it may be taken with or without food, but anyone who wants the fast window should not take it straight after a heavy meal. The registration trial placed no restrictions on food or alcohol. Efficacy held up regardless.

The US prescribing information gives a terminal half-life of about 5 hours, the EU SmPC 6 to 17 hours, depending on how long sampling continued after the dose. What matters in practice is the quick fall after the peak: far shorter than tadalafil (17.5 hours) and in the range of sildenafil. Avanafil is around 99 percent bound to plasma proteins and is cleared mainly through CYP3A4, with the metabolites leaving the body about 62 percent via the faeces and 21 percent via the urine. With daily dosing the accumulation ratio is about 1.2, so practically nothing builds up.

CYP3A4 clearance is where interactions arise. Ketoconazole raised the exposure of a 50mg dose 13-fold and stretched the half-life to about 9 hours; erythromycin, a moderate inhibitor, tripled exposure and extended the half-life to around 8 hours. In older men (65 to 80 years) exposure was only about 7 percent higher. The prescribing information sees no need for a dose adjustment on age alone.

Use and dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts
White folding box with the TPD logo next to a blister of ten round white tablets, two loose tablets in front on a bright lab bench
Tablets in a blister. Symbolic image.

Avanafil vs sildenafil vs tadalafil

The three differ less in potency than in time course and side effect profile:

  • Avanafil: lead time about 15 minutes, peak after 30 to 45 minutes, half-life about 5 hours (US figure), window beyond 6 hours. High selectivity over PDE1, PDE6 and PDE11 at once, a single participant with a colour vision change across all trials up to 200mg. Food matters little.
  • Sildenafil: lead time 30 to 60 minutes, duration about 4 to 6 hours. Sensitive to fatty food, a blue tinge to vision is possible (PDE6). The longest-established agent with the most data.
  • Tadalafil: window up to 36 hours, can also be dosed low daily. Back and muscle pain as its class-specific effect (PDE11), food barely matters.

In short: avanafil for spontaneity with a short lead time and a clean side effect profile, tadalafil for a long window or daily dosing, sildenafil as the classic with the broadest evidence base. Avanafil is not approved for daily low-dose use and there are no registration data for it.

Comparison

Four PDE-5 inhibitors side by side

All inhibit the same enzyme and differ in their time course, as stated in the TPD lexicon. Tap a card to open its entry.

Simplified: the selectivity over PDE1, PDE6 and PDE11 comes from a lab comparison, direct comparison trials in humans are missing. 5

What the research shows

Registration trial (Goldstein, Journal of Sexual Medicine 2012): 646 men with mild to severe erectile dysfunction received 50, 100 or 200mg avanafil or placebo for 12 weeks, taken 30 minutes before activity with no restrictions on food or alcohol. All three doses improved the success rate for intercourse (SEP3), penetration (SEP2) and the IIEF erectile function score significantly versus placebo. Of 300 attempts within 15 minutes of dosing, 64 to 71 percent succeeded on avanafil versus 27 percent on placebo. Of 80 attempts more than six hours after dosing, 59 to 83 percent succeeded versus 25 percent.

Stopwatch trial (Hellstrom, Journal of Urology 2015): 440 men, 100 or 200mg or placebo, with success timed by stopwatch to 15 minutes after dosing. Within that limit 25.9 percent of attempts succeeded on 100mg and 29.1 percent on 200mg, versus 14.9 percent on placebo. The difference was statistically significant from 10 minutes (200mg) and 12 minutes (100mg). That is the evidence for the short lead time, even though absolute rates within such a tight window are naturally lower than across a whole evening.

Hard populations: in 390 men with diabetes (Goldstein, Mayo Clinic Proceedings 2012), 100 and 200mg improved all three co-primary endpoints significantly, with the same window from 15 minutes to beyond six hours. After bilateral nerve-sparing radical prostatectomy (Mulhall, Journal of Urology 2013), 71.5 percent of the 298 participants had severe dysfunction, yet both doses met all three endpoints. Of the attempts within 15 minutes, 36.4 percent succeeded versus 4.5 percent on placebo.

Long term (Belkoff, International Journal of Clinical Practice 2013): 712 men from two of the phase 3 trials continued avanafil open-label for 52 weeks, initially on 100mg with the option of 200 or 50mg. The SEP3 success rate rose from 13 to 68 percent and the IIEF erectile function score from 13.6 to 22.2. Fewer than 3 percent discontinued because of adverse events. What is missing: data on daily low-dose use and head-to-head trials against sildenafil or tadalafil. The short lead time is well established; the claim of better tolerability rests on selectivity data and indirect comparisons.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Share of successful attempts at the end of the trial7

646 men with mild to severe erectile dysfunction, taken about 30 minutes before

Penetration possible (SEP2)7
Placebo 53.8%
Lowest study dose 64.3%
Middle study dose 73.9%
Highest study dose 77.3%
Intercourse successful (SEP3)7
Placebo 27.0%
Lowest study dose 41.3%
Middle study dose 57.1%
Highest study dose 57.0%

Values from the US label (study 1). Between the middle and highest dose there was hardly any difference in success, but there was in headache.

Success within about 15 minutes2

440 men, share of successful attempts per person, measured with a stopwatch

Stopwatch trial2
Placebo 14.9%
Middle study dose 25.9%
Highest study dose 29.1%

Significant from 10 minutes at the highest and from 12 minutes at the middle dose. In this narrow window the shares are naturally lower than over a whole evening.

Intercourse successful (SEP3) in difficult groups7

Share at the end of the trial after 12 weeks

With diabetes7 390 men
Placebo 20.5%
Middle study dose 34.4%
Highest study dose 40.0%
After prostate removal7 298 men, mostly severe dysfunction
Placebo 8.9%
Middle study dose 23.4%
Highest study dose 26.4%

Values from the US label (studies 2 and 3). After surgery 36.4 percent of attempts within 15 minutes were successful, 4.5 percent with placebo.

Row of sealed test tubes in front of a glowing red vessel band, a silver stopwatch to the right
One trial measured the onset with a stopwatch. Symbolic image.

Research status

Where the research stands

Avanafil has been approved in the US since 2012. ClinicalTrials.gov lists 24 trials with avanafil, one of them with unknown status (comparison with sildenafil after spinal cord injury) is not shown here. As of 26 Oct 2026. 9

  1. Preclinical Selectivity across eleven phosphodiesterases and erection in dogs
  2. Phase 1 11 trials, 11 completed
  3. Phase 2 1 trial, 1 completed
  4. Phase 3 7 trials, 7 completed
  5. Approval in the US since 2012
2,638 participants in phase 3 Approved: in the US since April 2012 (Drugs@FDA), ChEMBL lists avanafil with phase 4 as the highest phase.8
Show all 12 phase 2, 3 and 4 trials on a timelineHide timeline 12 completed 0 running 4 with results
Phase 2
Phase 3
Phase 4

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 11 trials on safety and pharmacokinetics, not shown as bars.

Side effects

  • Headache: the most common side effect and clearly dose-dependent: 5.1 percent on 50mg, 6.9 on 100mg, 10.5 on 200mg, versus 1.7 percent on placebo (pooled registration trials, prescribing information).
  • Flushing: facial redness in 3 to 4 percent, in nobody on placebo.
  • Nasal congestion and nasopharyngitis: 1 to 3 percent, with nasopharyngitis barely above placebo (2.9 percent). The stuffy nose is mechanism-driven as in the whole class.
  • Back pain: 1 to 3 percent, without a clear dose relationship.
  • Less common (1 to 2 percent): dyspepsia, nausea, constipation, rash, raised blood pressure, upper respiratory infections.
  • Vision and hearing: across all avanafil trials only a single participant reported a change in colour vision, per the US prescribing information, but the class warnings still apply: a sudden loss of vision (NAION) or a sudden loss of hearing is a reason to stop at once and seek medical help.
  • Priapism: rare, but any erection lasting more than four hours is an emergency.

The discontinuation rate for adverse events in the registration trials was 1.4 to 2.0 percent, on a par with placebo (1.7 percent). Over 52 weeks it was 2.8 percent.

Tolerability

Side effects compared with placebo

Out of 100 participants per group, how many had the event over 12 weeks.

2 of 100 Placebo
5 of 100 Lowest study dose
7 of 100 Middle study dose
11 of 100 Highest study dose
Event PlaceboLowest study doseMiddle study doseHighest study dose
Headache7 2%5%7%11%
Flushing7 0%3%4%4%
Nasal congestion7 1%2%3%2%
Back pain7 1%3%2%1%

Values from the US label. Across all trials a single participant reported a change in colour vision. In the 52-week extension fewer than 3 percent stopped because of side effects.76

Safety and interactions

The one rule that applies to the whole class and leaves even less room with avanafil because of its fast onset: never combine with nitrates. That includes nitroglycerin, isosorbide dinitrate and mononitrate as well as the alkyl nitrites sold as poppers. Both act on the same signalling chain. Together they can drop blood pressure to life-threatening levels. The prescribing information also lists guanylate cyclase stimulators such as riociguat (the US label adds vericiguat) as contraindications and requires at least 12 hours between the last avanafil dose and a nitrate in an emergency.

Blood pressure: alpha-blockers (tamsulosin, alfuzosin, doxazosin), other antihypertensives and more than three units of alcohol add to the blood pressure drop. The prescribing information advises against avanafil after a heart attack, stroke or revascularisation within the last six months, with resting blood pressure below 90/50 or above 170/100 mmHg, with unstable angina and with heart failure of NYHA class II or worse, simply because those groups were not in the trials. Sexual activity is physical exertion. Anyone with a cardiovascular history should clear this with a doctor first.

CYP3A4: strong inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir and other HIV protease inhibitors) raise exposure up to 13-fold and rule avanafil out. Moderate inhibitors (erythromycin, diltiazem, verapamil, fluconazole, aprepitant) cap the dose at 50mg in 24 hours. Grapefruit juice also inhibits CYP3A4. The EU SmPC advises avoiding it in the 24 hours before a dose.

Storage

Store dry, at room temperature and protected from light. Leave the tablets in the blister until you need them. Use a split 100mg tablet promptly rather than keeping the half around for weeks. Keep out of reach of children and mind the expiry date.

Three white tablet bottles on a bright shelf next to a folded light blue towel
Dry, at room temperature and away from light. Symbolic image.

Related

Related compounds

Same targets or a different path: all in the TPD lexicon.

FAQ

Common questions about Avanafil (Stendra, Spedra)

Short answers, each backed by the sources below.

How does avanafil work?

With arousal nerves in the erectile tissue release nitric oxide, the messenger cGMP rises and the vessels widen. PDE5 breaks cGMP down again. Avanafil inhibits PDE5 and the signal lasts longer. Without sexual stimulation the chain does not start.107

How fast does it work?

Fasted, the peak level is reached after 30 to 45 minutes. In the stopwatch trial with 440 men the difference from placebo was significant from 10 to 12 minutes. In the registration trial 64 to 71 percent of attempts within 15 minutes succeeded, 27 percent with placebo. A high-fat meal pushes the peak back.721

Is avanafil approved?

Yes. In the US since April 2012, ChEMBL lists it with phase 4 as the highest phase. ClinicalTrials.gov lists 24 trials, 7 of them completed phase 3 trials (as of 26 October 2026). Everything here is the state of research, not a recommendation.8109

What does the high selectivity mean?

In a lab comparison avanafil inhibited PDE6 in the retina 121-fold more weakly than PDE5, sildenafil and vardenafil only 16- to 21-fold. Over PDE1 the gap was more than 10,000-fold, over PDE11 more than 19,000-fold. Less binding to these off-targets suggests fewer visual disturbances and muscle pains, direct comparison trials are missing.5

Does it also work in diabetes or after prostate surgery?

In both groups yes, at a lower level. In 390 men with diabetes intercourse succeeded in 34 to 40 percent of attempts at the end, 20.5 percent with placebo. After nerve-sparing prostate removal (298 men, mostly severe dysfunction) it was 23 to 26 versus 8.9 percent.734

Why never with nitrates?

Nitrates and avanafil act on the same signalling chain, together blood pressure can fall to life-threatening levels. That also applies to poppers. The label requires at least 12 hours between the last dose and a nitrate in an emergency. Strong CYP3A4 inhibitors such as ketoconazole raise the level up to 13-fold.7

What did the long-term trial show?

712 men continued avanafil open-label for 52 weeks. At the middle dose the share of successful attempts rose from 13 to 68 percent. Of the men for whom the middle dose was not enough, 65 percent responded to the highest. Fewer than 3 percent stopped because of side effects.6

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

cGMP
A messenger inside the cell that relaxes vessel muscle. PDE5 breaks it down.
CYP3A4
Liver enzyme that breaks down avanafil. If something inhibits it, the level rises sharply.
Half-life
The time until the amount in the blood has fallen by half.
IC50
The concentration at which a compound inhibits an enzyme by half. The smaller, the stronger.
NAION
Sudden loss of vision from reduced blood flow to the optic nerve. A rare class warning for PDE-5 inhibitors.
Nitrates
Vessel-widening drugs such as nitroglycerin and the alkyl nitrites sold as poppers.
Nitric oxide
A gaseous messenger (NO) that relaxes smooth muscle and widens vessels.
PDE-5 inhibitor
A class of compounds that slows the enzyme PDE5. It includes avanafil, sildenafil, tadalafil and vardenafil.
PDE5
Enzyme in the erectile tissue that breaks down cGMP and so ends the erection.
PDE6
A related enzyme in the retina. Its inhibition explains the blue tinge in vision.
Selectivity
How strongly a compound prefers its target. High selectivity means little effect on other enzymes.
SEP3
Question 3 of the trial diary: did the erection last long enough for successful intercourse?

Evidencia

Fuentes

Show all 10 sourcesHide sources 6 Studies1 Trial registry3 Database checked 26 Oct 2026

Studies

  1. Registration trial with 646 men over 12 weeks

    Goldstein et al., Journal of Sexual Medicine, 2012

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Stopwatch trial: effect within 15 minutes

    Hellstrom et al., Journal of Urology, 2015

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Avanafil in 390 men with diabetes

    Goldstein et al., Mayo Clinic Proceedings, 2012

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Phase 3 after nerve-sparing prostate removal

    Mulhall et al., Journal of Urology, 2013

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Selectivity across eleven phosphodiesterases compared

    Kotera et al., Journal of Urology, 2012

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. Open-label extension over 52 weeks

    Belkoff et al., International Journal of Clinical Practice, 2013

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Trials on avanafil on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. US prescribing information for avanafil

    DailyMed, U.S. National Library of Medicine (Stand 17.12.2025)

    Checked 26 Oct 2026 via DailyMed, openFDA
  2. First approval in the US (NDA 202276)

    Drugs@FDA, U.S. Food and Drug Administration

    Checked 26 Oct 2026 via Drugs@FDA, openFDA
  3. Mechanism in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL1963681)

    Checked 26 Oct 2026 via ChEMBL

En la tienda

Avanafil (Stendra, Spedra) in the catalog

Los tamaños, precios y plazos de envío están en la página del producto.

Ir al producto